Table 3.
Change in Lipid Profile and Fatty Acid Fractions
| Control Group (n=31) | EPA Group (n=31) | EPA+DHA Group (n=35) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Follow‐Up | P Value | Baseline | Follow‐Up | P Value | Baseline | Follow‐Up | P Value | |
| Triglycerides, mg/dL | 106 (73–141) | 152 (107–172) | 0.003 | 117 (91–135) | 119 (85–162) | 0.425 | 96 (67–131) | 133 (99–164) | 0.123 |
| Total cholesterol, mg/dL | 183 (166–215) | 145 (138–172) | <0.0001 | 195 (162–217) | 152 (140–165) | <0.0001 | 182 (163–207) | 164 (135–177) | <0.0001 |
| LDL‐C, mg/dL | 125 (105–140) | 78 (61–96) | <0.0001 | 120 (99–142) | 78 (65–95) | <0.0001 | 118 (99–145) | 82 (60–103) | <0.0001 |
| HDL‐C, mg/dL | 43 (36–48) | 43 (36–51) | 0.985 | 45 (38–51) | 49 (42–56) | 0.053 | 46 (38–54) | 44 (37–52) | 0.880 |
| EPA, mg/dL | 43.0 (29.2–62.5) | 55.7 (43.0–76.5) | 0.014 | 37.0 (29.3–66.1) | 170.1 (145.4–212.0)* | <0.0001 | 45.2 (32.9–66.3) | 122.3 (100.5–147.4)* | 0.0001 |
| AA, mg/dL | 165.1±41.7 | 184.8±52.5 | 0.013 | 163.4±36.3 | 159.7±39.5* | 0.082 | 163.1±46.5 | 164.5±37.3 | 0.503 |
| DHA, mg/dL | 112.8±32.8 | 114.9±31.3 | 0.848 | 112.5±36.7 | 106.7±31.6 | 0.568 | 113.1±29.9 | 140.7±44.6* | <0.0001 |
| EPA/AA ratio | 0.31 (0.20–0.43) | 0.35 (0.21–0.50) | 0.328 | 0.26 (0.15–0.43) | 1.15 (0.88–1.61)* | <0.0001 | 0.33 (0.18–0.40) | 0.75 (0.60–0.98)* | <0.0001 |
Values are presented as mean±SD or median (interquartile interval). AA indicates arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; HDL‐C, high‐density lipoprotein cholesterol; and LDL‐C, low‐density lipoprotein cholesterol.
*
P<0.05 vs control group.